Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-fca2b0949c2af4853c1cd5b425813585"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-fca2b0949c2af4853c1cd5b425813585"/>
<resource>
<Composition>
<id value="composition-en-fca2b0949c2af4853c1cd5b425813585"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-fca2b0949c2af4853c1cd5b425813585"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-fca2b0949c2af4853c1cd5b425813585</b></p><a name="composition-en-fca2b0949c2af4853c1cd5b425813585"> </a><a name="hccomposition-en-fca2b0949c2af4853c1cd5b425813585"> </a><a name="composition-en-fca2b0949c2af4853c1cd5b425813585-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1530/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - ontozry</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/21/1530/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpfca2b0949c2af4853c1cd5b425813585"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - ontozry"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Ontozry is and what it is used for</li><li>What you need to know before you take Ontozry</li><li>How to take Ontozry</li><li>Possible side effects</li><li>How to store Ontozry</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What ontozry is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What ontozry is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Ontozry contains the active substance cenobamate. It belongs to a group of medicines called anti- epileptics . These medicines are used to treat epilepsy, a condition where someone has seizures or fits because of abnormal activity in the brain.</p><p>Ontozry is used in combination with other antiepileptic medicines in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic products, to treat a type of epilepsy that has focal-onset seizures with or without secondary generalisation. Focal-onset seizures are those caused by abnormal brain activity starting in a part of the brain on one side, and secondary generalisation means that that the abnormal activity is spreading to both sides of the brain. The medicine can be used only in adults.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take ontozry"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take ontozry"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Ontozry</p><ul><li>if you are allergic to cenobamate or any of the other ingredients of this medicine (listed in section 6).</li><li>you were born with heart problems, with changes in the electrical activity of the heart, related to a rare condition called familial short-QT syndrome.</li></ul><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Ontozry or during treatment if:</p><ul><li>you have thoughts of harming or killing yourself. A few people being treated with anti-epileptic medicines such as Ontozry have had thoughts of harming or killing themselves. If you have any of these thoughts at any time, contact your doctor immediately.</li><li>you have a serious skin reaction which may include high temperature and other flu-like symptoms, rash on the face, rash spreading to other parts of the body, swollen glands (enlarged lymph nodes); and blood tests showing increased levels of liver enzymes and of a type of white blood cell (eosinophilia).</li><li></li></ul><p>Children and adolescents</p><p>Ontozry is not recommended in children and adolescents under 18 years, as it was not investigated in this group.</p><p>Other medicines and Ontozry</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Taking Ontozry with certain other medicines may affect how the other medicines work or how Ontozry works. Do not start or stop other medicines without talking to your doctor or pharmacist.</p><p>Tell your doctor if you are taking any of the following medicines, as your dose may need to be adjusted:</p><ul><li>medicines used to help you fall asleep such as barbiturates and benzodiazepines.</li><li>other medicines to treat epilepsy, such as clobazam, phenytoin and phenobarbital, lamotrigine.</li><li>birth control medicines (oral contraceptives) as these may be less effective when combined with Ontozry. Your doctor may prescribe alternative methods for preventing pregnancy while you take this medicine and up to 4 weeks after you stop taking this medicine.</li><li>medicines, which are known to be transformed in the body by specific groups of enzymes such as midazolam (a medicine used to stop prolonged, acute (sudden) convulsive seizures, for sedation and sleep problem), bupropion (a medicine used to help stop smoking), omeprazole (a medicine used to treat heartburn or stomach ulcer), baricitinib (a medicine used to treat painful inflammation of the joints or skin eczema), cefaclor (an antibiotic), empagliflozin (a medicine used to treat high blood glucose in diabetes), penicillin G (an antibiotic), ritobegron (a medicine used to treat overactive bladder), sitagliptin (a medicine used to control high blood glucose in diabetes).</li></ul><p>Ontozry with alcohol</p><p>Do not take this medicine with alcohol. Ontozry can increase the effects of alcohol such as feeling tired or sleepy and you should not drink alcohol with this medicine.</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before you take this medicine. Only take Ontozry during pregnancy if you and your doctor decide that it is absolutely necessary. You must use effective contraception during use of cenobamate and until 4 weeks after you stop taking this medicine. Ask your doctor for advice regarding effective measures of birth control. You should stop breast-feeding while taking Ontozry.</p><p>Driving and using machines</p><ul><li>You may feel sleepy, dizzy or tired, and your vision may be reduced while taking Ontozry.</li><li>These effects are more likely at the start of the treatment or after your dose is increased.</li><li>Do not drive, cycle or use any tools or machines if your reaction are slowed down and until you know how the medicine affects you.</li></ul><p>Ontozry contains lactose</p><p>If you have been told by your doctor that you have an intolerance to some sugars, speak with your doctor before taking this medicine.</p></div>
</text>
</section>
<section>
<title value="3. How to take ontozry"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take ontozry"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>You will take Ontozry with other medicines to treat epilepsy.</p><p>The recommended dose is You will start Ontozry with a daily dose of one 12.5 mg tablet for the first 2 weeks, followed by one 25 mg tablet once a day for the next 2 weeks. Then your dose will be gradually adjusted every 2 weeks until you reach the dose that works best. Your doctor will work out the right daily dose for you and may need to adjust it over time. The recommended daily dose is between 200 mg and 400 mg once daily.</p><p>Method of use Take the recommended dose once a day at around the same time. You can take Ontozry at any time either during the day or in the evening, with food or between meals.</p><p>Swallow the tablets whole with a glass of water. Do not break the tablets in half because the tablets are not suitable for splitting into two equal halves.</p><p>If you take more Ontozry than you should</p><p>Talk to your doctor. You may feel dizzy, tired and sleepy.</p><p>If you forget to take Ontozry</p><p>Take the forgotten dose as soon as you remember, if fewer than 12 hours have passed since you should have taken it. If more than 12 hours have passed, skip the forgotten dose and take the next dose at your regular time. Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Ontozry</p><p>Do not reduce the dose or stop taking Ontozry without checking with your doctor. Your doctor will explain how to stop taking Ontozry by reducing the dose gradually.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately if you have any of the following serious side effects:<br/>Rare side effects (may affect up to 1 in 1,000 people):</p><ul><li>a serious skin reaction which may include fever and other flu-like symptoms, a rash on the face, rash spreading to other areas of the body, and swollen glands (enlarged lymph nodes). Blood tests may show increased levels of liver enzymes and of a type of white blood cell (eosinophilia).</li></ul><p>You may get the following other side effects with this medicine. Tell the doctor if you have any of the following: Very common side effects (may affect more than 1 in 10 people):</p><ul><li>feeling sleepy (somnolence), sedated or very tired (fatigue)</li><li>feeling dizzy</li><li>spinning sensation (vertigo)</li><li>having problems with coordination of movements, having problems walking or keeping your balance (ataxia, gait disturbance, abnormal coordination)</li><li>headache</li></ul><p>Common side effects (may affect up to 1 in 10 people):</p><ul><li>reduced memory, confusion</li><li>excitability</li><li>having difficulty in saying words or difficulty speaking</li><li>rapid and uncontrollable movements of the eyes (nystagmus), blurred vision, double vision</li><li>nausea (feeling sick), vomiting, constipation or diarrhoea</li><li>dry mouth</li><li>rash, itching</li><li>swollen eyelids, swollen limbs</li><li>blood tests showing increases in levels of certain liver enzymes</li></ul><p>Uncommon side effects (may affect up to 1 in 100 people):</p><ul><li>allergic reactions</li><li>thoughts of harming or killing yourself.</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store ontozry"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store ontozry"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Ontozry contains</p><ul><li>The active substance is cenobamate. One Ontozry 12.5 mg tablet contains 12.5 mg cenobamate. One Ontozry 25 mg film-coated tablet contains 25 mg cenobamate. One 50 mg film-coated tablet contains 50 mg cenobamate. One 100 mg film-coated tablet contains 100 mg cenobamate. One 150 mg film-coated tablet contains 150 mg cenobamate. One 200 mg film-coated tablet contains 200 mg cenobamate.</li><li>The other ingredients are microcrystalline cellulose (E460), lactose monohydrate, sodium starch glycolate, silica colloidal anhydrous (E551), magnesium stearate (E470b)</li></ul><p>25 mg and 100 mg film-coated tablets: indigo carmine aluminium lake (E132), iron oxide red (E172), iron oxide yellow (E172), -macrogol, partially hydrolysed poly(vinyl alcohol) (E1203), talc (E553b), titanium dioxide (E171)</p><p>50 mg film-coated tablets: iron oxide yellow (E172), macrogol, partially hydrolysed poly(vinyl alcohol) (E1203), talc, titanium dioxide (171)</p><p>150 mg and 200 mg film-coated tablets: iron oxide red (E172), iron oxide yellow (E172), macrogol, partially hydrolysed poly(vinyl alcohol) (E1203), talc (E553b), titanium dioxide (E171)</p><p>What Ontozry looks like and contents of the pack</p><p>Ontozry 12.5 mg are uncoated round white to off-white tablets with AV on one side and 12 on the other side.<br/>Ontozry 25 mg are round brown film-coated tablets with AV on one side and 25 on the other side. Ontozry 50 mg are round yellow film-coated tablets with AV on one side and 50 on the other side. Ontozry 100 mg are round brown film-coated tablets with AV on one side and 100 on the other side. Ontozry 150 mg are round light orange film-coated tablets with AV on one side and 150 on the other side.<br/>Ontozry 200 mg are oval light orange film-coated tablets with AV on one side and 200 on the other side.</p><p>Ontozry Treatment Initiation pack contains 14 tablets of 12.5 mg and 14 film-coated tablets of 25 mg.</p><p>Ontozry 50 mg, 100 mg, 150 mg and 200 mg film-coated tablets are available in packs of 14, 28 or 84. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder</p><p>Angelini Pharma S.p.A Viale Amelia 70, 00Rome Italy</p><p>Manufacturer</p><p>Swiss Caps GmbH Grassingerstrasse 9 83043 Bad Aibling Germany</p><p>Aziende Chimiche Riunite Angelini Francesco ACRAF SPA Via Vecchia del Pinocchio, 22 60Ancona (AN), Italy</p><p>This leaflet was last revised in.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency website: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</p><p>Annex IV Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)</p><p>Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for cenobamate, the scientific conclusions of PRAC are as follows:<br/>In view of available data from clinical trials and spontaneous reports, including 11 Individual Case Safety Reports with a close temporal relationship and a positive de-challenge, the PRAC considers a causal relationship between cenobamate and suicidal ideation is at least a reasonable possibility. The PRAC concluded that the product information of products containing cenobamate should be amended accordingly. Having reviewed the PRAC recommendation, the CHMP agrees with the PRAC overall conclusions and grounds for recommendation. Grounds for the variation to the terms of the marketing authorisation(s) On the basis of the scientific conclusions for cenobamate the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing cenobamate is unchanged subject to the proposed changes to the product information The CHMP recommends that the terms of the marketing authorisation(s) should be varied.</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpfca2b0949c2af4853c1cd5b425813585"/>
<resource>
<MedicinalProductDefinition>
<id value="mpfca2b0949c2af4853c1cd5b425813585"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpfca2b0949c2af4853c1cd5b425813585"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpfca2b0949c2af4853c1cd5b425813585</b></p><a name="mpfca2b0949c2af4853c1cd5b425813585"> </a><a name="hcmpfca2b0949c2af4853c1cd5b425813585"> </a><a name="mpfca2b0949c2af4853c1cd5b425813585-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1530/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Ontozry 12.5 mg tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/21/1530/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Ontozry 12.5 mg tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
